INTRODUCTION
Staphylococcus aureus (S. aureus) infections are a major cause of pneumonia and are especially implicated in hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and healthcare-associated pneumonia [1] . The recent Infectious Diseases Society of America guidelines recommend treating HAP/VAP patients with either vancomycin or linezolid [2] . Higher vancomycin minimum inhibitory concentrations (MICs) have been associated with more frequent treatment failure and higher mortality rates [3] [4] [5] [6] . Telavancin (Theravance Biopharma Antibiotics, Inc., George Town, Grand Cayman, Cayman Islands) is a parenteral bactericidal lipoglycopeptide antibiotic that has a dual mechanism of action [7] [8] [9] [10] . Telavancin is approved in the US, Canada, Russia, and Europe for treatment of HAP, including VAP that is caused by susceptible isolates of S. aureus (methicillin-resistant S. aureus [MRSA] only in Europe). In the US, Russia, and Europe, the indication is limited to infections in which alternative medicines are unsuitable [8, 11, 12] .
In the Assessment of Telavancin for Treatment of Hospital-Acquired Pneumonia [ATTAIN (ClinicalTrials.gov identifiers NCT00107952
and NCT00124020)] studies, a total of 1503 patients with HAP were treated with telavancin or vancomycin for up to 21 days. Telavancin demonstrated noninferiority to vancomycin, achieving similar cure rates [13] .
Drug loss due to binding to plastics in the MIC assay has been found with other lipoglycopeptides and is resolved with the addition of polysorbate 80 (P-80) [14, 15] 
METHODS

Patient Population and Study Procedures
The protocol for the ATTAIN studies has been presented elsewhere [13] . Briefly, these were 
Clinical Isolates
Isolates were sent from the ATTAIN study central laboratories (Covance Laboratories) to JMI Laboratories for retesting using the rBMD method. The isolates were stored at -80°C at Covance, then were shipped to JMI laboratories on dry ice, where they were stored at -80°C. were within acceptable ranges defined by CLSI [16] .
Statistical Analyses
All the analyses were descriptive and performed using SAS Ò 9.4 software (Cary, NC, USA).
Compliance with Ethics Guidelines
This article is based on previously conducted studies, and does not involve any new studies of human or animal subjects performed by any of the authors.
RESULTS
A total of 647 S. aureus isolates from patients with HAP in the ATTAIN studies were analyzed for telavancin MICs using the rBMD method (644 samples were tested using the original method). Three isolates that did not have an initial central laboratory MIC result and were not included in the original susceptibility analysis were included in this set of retested isolates. Overall, 240 isolates were MSSA isolates, and 407 were MRSA isolates.
The MIC values obtained using the rBMD method for telavancin and control agents tested against ATTAIN S. aureus isolates were within the CLSI-approved and accepted QC ranges determined using S. aureus ATCC 29213
(telavancin 0.03-0.12 lg/mL, ampicillin 0.5-2.0 lg/mL, linezolid 1.0-4.0 lg/mL, vancomycin 0.5-2.0 lg/mL) [16] .
Telavancin MICs for all S. aureus isolates ranged from 0.015 to 0.12 lg/mL, with a range of 0.015 to 0.12 lg/mL for MSSA isolates and 0.015 to 0.12 lg/mL for MRSA isolates ( A total of 183 isolates exhibited a ±1 dilution change in the vancomycin MIC C1 lg/mL upon retesting. Of those, 1 increased from 0.25 to 0.5 lg/mL, 110 increased from 0.5 to C1 lg/mL, 11 increased from 1 to 2 lg/mL, 50 decreased from 1 to 0.5 lg/mL, and 11 decreased from 2 to 1 lg/mL. A total of 2 isolates exhibited a 2-dilution change in the vancomycin MIC upon retesting with 1 increasing from 0.5 to 2.0 lg/mL and 1 decreasing from 2.0 to 0.5 lg/ mL. These changes can be attributed to random testing differences between two laboratories ( 
DISCUSSION
Lipoglycopeptide drug loss due to its binding to plastics is known to affect the MIC determination. The addition of P-80 to the MIC assay has resolved this issue and the FDA-approved rBMD method includes DMSO and P-80 to improve drug solubility and reduce drug loss, respectively [8, [14] [15] [16] [17] . Telavancin is a lipoglycopeptide active against a wide range of susceptible Gram-positive pathogens, including S. aureus [13] . The objective of this study was to Telavancin MIC values for MSSA and MRSA obtained using the rBMD method were lower than those that have been published elsewhere using the original method [21, 22] , indicating that telavancin is more active in vitro against S. aureus isolates than previously considered. In this study, the rBMD method produced an overall 4-fold decrease in the telavancin MIC 50/90 for S. aureus compared with the original method. All isolates were susceptible to telavancin, consistent with other studies reporting telavancin susceptibility of S. aureus using the rBMD method [18, 19] . Telavancin also retained its in vitro potency against isolates with reduced susceptibility to vancomycin (MIC C1 lg/mL). Furthermore, the reassessment of ATTAIN study clinical isolates using the rBMD method demonstrated robust clinical cure and microbiological eradication even at the highest telavancin MIC (0.12 lg/mL) observed in the study.
This study is limited by its retrospective nature. The patients were not prospectively stratified by MIC and the reduced sample size prevented extensive statistical analyses of the clinical cure rates. However, the Clopper-Pearson (Exact) confidence interval method [22] was applied to demonstrate that the clinical cure rates were comparable across all S. aureus isolates and telavancin MICs. 
